Syndax Pharmaceuticals (SNDX) Tops Q2 EPS by 13c, Beats on Revenues; Offers FY17 OpEx Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Syndax Pharmaceuticals (SNDX) PT Lowered to $20 at Citi; Reiterates Buy
August 11, 2017 8:56 AM EDTCiti lowered its price target on Syndax Pharmaceuticals (NASDAQ: SNDX) to $20.00 (from $24.00) while maintaining a Buy rating. Citi... More
Syndax Pharmaceuticals (SNDX) PT Lowered to $22 at Nomura/Instinet on Mixed 2Q Results
August 11, 2017 8:54 AM EDTNomura/Instinet lowered its price target on Syndax Pharmaceuticals (NASDAQ: SNDX) to $22.00 (from $27.00) while maintaining a Buy rating, following the company's second quarter earnings report.
Analyst Christopher Marai notes the company delivered second quarter earnings per share below expectations, despite revenues in-line with estimates,... More
